Diversified Pipeline of Critical Care Products | Citius Pharmaceuticals

Published on: December 8, 2023
Author: Editor

We are honored to invite Leonard Mazur, Co-Founder, CEO, and Chairman of the Board of Citius Pharmaceuticals, to this interview again to introduce the company’s overview and the progress of related major pharmaceutical products. Leonard emphasized that Citius has a diversified pipeline including two late-stage product candidates: LYMPHIR™ and Mino-Lok®. Also, Citius has $33.3 M cash as of 6/30/2023 with runway through August 2024.

About Citius Pharmaceuticals (NASDAQ: CTXR)

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company’s diversified pipeline includes two late-stage product candidates. Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, is enrolling patients in a Phase 3 Pivotal superiority trial and was granted Fast Track designation by the FDA. Citius Pharma is preparing to resubmit the Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), in early 2024, and announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, at the end of March 2023, Citius Pharma completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit their website.

NAI500’s CEO Interview series is a program where we invite CEOs and senior executives of exciting public companies to uncover great investment opportunities for everyday investors. If you don’t want to miss out on the great opportunities that we bring, subscribe to our YouTube channel and other social media channels below!

Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.

Biotechnology CEO Interview Pharmaceutical